drugset / Trial / NCT07008196
Telitacicept for the Treatment of Refractory RA
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, open-label, prospective study on the efficacy and safety of Telitacicept in patients with refractory rheumatoid arthritis.
Timeline
- Start
- 2025-06-10
- Primary completion
- 2025-12
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |